Skip to main content
Company profile
MediWound Ltd. logo

MediWound Ltd.

Pipeline3 assets

Latest news7 items

All news

MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update

EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under its BARDA Contract for NexoBrid ® Second Quarter Revenue of $3.1 Million; Full-Year 2026 Revenue Guidance of $24–26

Enrollment • Phase 3Enrollment completion Wed, Mar 31, 2027

MediWound to Report Second Quarter 2026 Financial Results

MediWound to Report Second Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, August 13 at 8:30 a.m. Eastern Time YAVNE, Israel, July 29, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

EscharEx ® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue guidance reaffirmed at $24-26 million Conference Call Today, May 27, 2026, at 8:30 a.m.

Enrollment • Phase 3Enrollment completion Wed, Mar 31, 2027, 8:30 AM ET

MediWound to Report First Quarter 2026 Financial Results

MediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Wednesday, May 27 th at 8:30 a.m. Eastern Time YAVNE, Israel, May 7, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced

MediWound Ltd. • Endpoint Arena